Diaceutics PLC Issue of Share Options and PDMR Shareholdings (7394D)
01 Julio 2021 - 01:00AM
UK Regulatory
TIDMDXRX
RNS Number : 7394D
Diaceutics PLC
01 July 2021
1 July 2021
Diaceutics PLC
("Diaceutics" or "the Company")
Issue of Share Options and PDMR Shareholdings
Diaceutics PLC , ( AIM: DXRX), the diagnostic commercialisation
company for precision testing announces the issue of share options
over ordinary shares of GBP0.002 each in the Company ("Share
Options") on 30 June 2021, to certain members of the Company's
senior management team and other key staff. These share options
have been issued pursuant to certain contractual share-based
entitlements in place prior to the Company's IPO and are governed
by the rules of the Company's Employee Share Option Plan
("ESOP").
Share Options were granted as follows:
Name Number of Share Total no. of ordinary % of existing
Options granted shares under option issued share
post grant capital
Damian Thornton (COO
and PDMR) 4,200 170,996 0.2%
---------------- --------------------- -------------
Susanne Munksted (CPO
and PDMR) 4,200 70,672 0.08%
---------------- --------------------- -------------
A further 147,000 Share Options were granted to 35 employees,
each of whom received 4,200 Share Options.
The Share Options vest in full after three years following date
of grant subject to the grantee receiving no more than two
"unsatisfactory" performance ratings in their individual
performance reviews in the three-year period from the date of
grant. The exercise price of the Share Options is GBP0.002 per
share being the nominal value of the share.
Following the grant the total number of share options
outstanding granted to the Company's Directors, senior management
team and key employees is 2,237,170, representing approximately
2.7% of the Company's current issued share capital of
84,068,923.
Enquiries:
Diaceutics PLC
Philip White, Chief Financial Officer Via Alma PR
Stifel Nicolaus Europe Limited (Nomad & Broker) Tel: +44 (0)20 7710
7600
Ben Maddison
Stewart Wallace
Nick Adams
Alma PR Tel: +44(0)20 3405
0205
Caroline Forde diaceutics@almapr.co.uk
Robyn Fisher
Kieran Breheny
About Diaceutics
At Diaceutics we believe that every patient should have access
to the right treatment at the right time. We provide the world's
leading pharmaceutical companies with an end-to-end solution for
the launch of precision medicine diagnostics enabled by DXRX - The
Diagnostic Network(R).
DXRX is the world's first diagnostic commercialisation platform
for precision medicine, integrating multiple pipelines of
real-world diagnostic testing data from a global network of
laboratories.
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
------ --------------------------------------------------------------------------------------
a. Name Damian Thornton
------------------------------------------
2 Reason for notification
------------------------------------------ ------------------------------------------
a. Position/Status Chief Operating Officer
------------------------------------------ ------------------------------------------
b. Initial notification/ Initial
Amendment
------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
------------------------------------------
b. LEI 213800VEWQBB39ZB8J81
------------------------------------------ ------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
------ --------------------------------------------------------------------------------------
a. Description of Ordinary shares of GBP 0.002 each
the financial
instrument, type ISIN: GB00BJQTGV64
of instrument
Identification
Code
------------------------------------------ ------------------------------------------
b. Nature of the Grant of Share Options
transaction
------------------------------------------ ------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
------------------------------------------ ------------------
GBP0.002 4,200
-------------------------------------------------------------------- -----------------
d. Date of the transaction 30 June 2021
------------------------------------------ ------------------------------------------
e. Place of the transaction Outside a Trading Venue
------------------------------------------ ------------------------------------------
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
------ --------------------------------------------------------------------------------------
a. Name Susanne Munksted
------------------------------------------
2 Reason for notification
------------------------------------------ ------------------------------------------
a. Position/Status Chief Precision Officer
------------------------------------------ ------------------------------------------
b. Initial notification/ Initial
Amendment
------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
------------------------------------------
b. LEI 213800VEWQBB39ZB8J81
------------------------------------------ ------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
------ --------------------------------------------------------------------------------------
a. Description of Ordinary shares of GBP 0.002 each
the financial
instrument, type ISIN: GB00BJQTGV64
of instrument
Identification
Code
------------------------------------------ ------------------------------------------
b. Nature of the Grant of Share Options
transaction
------------------------------------------ ------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
------------------------------------------ ------------------
GBP0.002 4,200
-------------------------------------------------------------------- -----------------
d. Date of the transaction 30 June 2021
------------------------------------------ ------------------------------------------
e. Place of the transaction Outside a Trading Venue
------------------------------------------ ------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHEAKKEDSKFEFA
(END) Dow Jones Newswires
July 01, 2021 02:00 ET (06:00 GMT)
Diaceutics (LSE:DXRX)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Diaceutics (LSE:DXRX)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024